BioXcel Therapeutics CEO Vimal Mehta's Stock Transactions and Holdings

This Form 4 filing discloses transactions by BioXcel Therapeutics CEO and President Vimal Mehta involving company stock. On May 4, 2026, Mehta received 49,758 shares of common stock through the vesting of restricted stock units (RSUs) at $0 per share, increasing his direct holdings to 89,017 shares. Subsequently, on May 20, 2026, he sold 19,419 shares at a weighted average price of $1.087 per share, reducing his direct holdings to 69,598 shares. The sale was executed under a Rule 10b5-1 trading plan adopted on February 3, 2026, specifically to cover taxes related to RSU vesting. Additionally, Mehta has indirect beneficial ownership of 480,343 shares through BioXcel LLC and 125 shares held by his spouse. The RSUs were part of a 199,032-unit grant on January 1, 2026, with vesting scheduled over two years beginning November 4, 2025.